The estimated Net Worth of Capital Management, L.P.Ra ... is at least $115 million dollars as of 13 March 2020. Capital Ra owns over 6,337,135 units of Satsuma Pharmaceuticals stock worth over $11,962,074 and over the last 11 years Capital sold STSA stock worth over $102,695,404.
Capital has made over 21 trades of the Satsuma Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently Capital bought 6,337,135 units of STSA stock worth $49,999,995 on 13 March 2020.
The largest trade Capital's ever made was buying 6,337,135 units of Satsuma Pharmaceuticals stock on 13 March 2020 worth over $49,999,995. On average, Capital trades about 1,092,544 units every 84 days since 2013. As of 13 March 2020 Capital still owns at least 10,874,613 units of Satsuma Pharmaceuticals stock.
You can see the complete history of Capital Ra stock trades at the bottom of the page.
Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... et Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include: